Labcorp (LH)
(Delayed Data from NYSE)
$207.67 USD
+1.52 (0.74%)
Updated May 10, 2024 04:00 PM ET
After-Market: $207.71 +0.04 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$207.67 USD
+1.52 (0.74%)
Updated May 10, 2024 04:00 PM ET
After-Market: $207.71 +0.04 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Zacks News
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
by Zacks Equity Research
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
Integer Holdings (ITGR) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
by Zacks Equity Research
Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
by Urmimala Biswas
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
Merit Medical (MMSI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exploring Analyst Estimates for Labcorp (LH) Q1 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Labcorp (LH) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
by Nalak Das
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Revised)
by Zacks Equity Research
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Labcorp (LH) Could Beat Earnings Estimates Again
by Zacks Equity Research
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Should Value Investors Buy Labcorp (LH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Labcorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.
Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod
by Zacks Equity Research
Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.
Myriad Genetics (MYGN) Announces Favorable Research Results
by Zacks Equity Research
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes
by Zacks Equity Research
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
Labcorp (LH) Extends MRD Clinical Research With New Launch
by Zacks Equity Research
Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
by Zacks Equity Research
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
by Zacks Equity Research
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
by Zacks Equity Research
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.